The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adaptimmune SPONDS ADR 00653A107 3,390 250,000 SH   DFND   250,000 0 0
Aurinia Pharma Common 05156V102 2,655 400,434 SH   DFND   400,434 0 0
Aveo Pharma Common 053588109 1,316 400,000 SH   DFND   400,000 0 0
Cellectis SPONDS ADR 15117K103 2,823 100,000 SH   DFND   100,000 0 0
Chiasma Common 16706W102 7,490 2,080,595 SH   DFND   2,080,595 0 0
Crispr NAMEN AKT H17182108 54,858 1,237,202 SH   DFND   1,237,202 0 0
Cymabay Common 23257D103 3,027 273,417 SH   DFND   273,417 0 0
Histogenix Common 43358V109 473 888,889 SH   DFND   888,889 0 0
Immune Design Common 45252L103 1,198 352,300 SH   DFND   352,300 0 0
Obseva Common H5861P103 7,938 440,000 SH   DFND   440,000 0 0
Paratek Common 699374302 10,047 1,041,131 SH   DFND   1,041,131 0 0
Proteon Common 74371L109 3,834 2,017,872 SH   DFND   2,017,872 0 0
Sientra Common 82621J105 52,512 2,199,012 SH   DFND   2,199,012 0 0
Sierra Oncology Common 82640U107 2,456 1,444,445 SH   DFND   1,444,445 0 0
Ultragenyx Common 90400D108 2,910 38,100 SH   DFND   38,100 0 0
Verona SPONDS ADR 925050106 11,274 901,943 SH   DFND   901,943 0 0